The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?

Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.

wallstreetcnNov 30 21:01 ET

Wednesday Ends With Index Decline | Wall Street Today

Kevin TraversNov 27 16:08 ET

RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330

BenzingaNov 27 12:02 ET · Ratings

Amgen Analyst Ratings

BenzingaNov 27 12:01 ET · Ratings

Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock

Kevin TraversNov 27 09:57 ET

Trump Taps Jay Bhattacharya to Lead National Institutes of Health

Seeking AlphaNov 27 06:23 ET